MorphoSys (ETR:MOR – Get Rating) has been given a €11.00 ($11.70) price objective by JPMorgan Chase & Co. in a research report issued to clients and investors on Monday, Borsen Zeitung reports. JPMorgan Chase & Co.'s price target indicates a potential downside of 21.26% from the company's current price.
Several other equities research analysts have also issued reports on the stock. Morgan Stanley set a €12.50 ($13.30) price target on shares of MorphoSys in a research note on Friday. The Goldman Sachs Group set a €12.00 ($12.77) price target on shares of MorphoSys in a research note on Tuesday, January 3rd. Finally, Deutsche Bank Aktiengesellschaft set a €13.00 ($13.83) price objective on shares of MorphoSys in a research report on Friday, November 25th.
Get MorphoSys alerts:MorphoSys Stock Up 3.2 %
Shares of MOR stock opened at €13.97 ($14.86) on Monday. The company has a current ratio of 3.76, a quick ratio of 3.49 and a debt-to-equity ratio of 231.51. MorphoSys has a 1 year low of €13.90 ($14.79) and a 1 year high of €36.02 ($38.32). The firm's fifty day moving average price is €15.61 and its two-hundred day moving average price is €18.73. The firm has a market capitalization of $477.22 million and a P/E ratio of -0.79.
About MorphoSys
(Get Rating)MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma.
Featured Stories
- Will LI Auto Be the Least Hated Chinese EV Stock in 2023?
- Here's Why Snap Stock Can Double in 2023
- Which Streaming Service Stock is Best in 2023?
- MarketBeat: Week in Review 01/02-01/06
- Why is the CrowdStrike Stock Price Struggling?
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.